The Filing Desk

Nexalin Technology vs Pulse Biosciences

Nexalin Technology NXL · Pulse Biosciences PLSE · Health Care Equipment

Nexalin Technology reported revenue of $0 million in fiscal 2025, about the same as Pulse Biosciences' $0 million in fiscal 2025. Nexalin Technology had an operating margin of -2781.7%, against -21982.6% at Pulse Biosciences.

Side by side

Nexalin TechnologyPulse Biosciences
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$0M$0M
Revenue growth78.8%—
Revenue growth a year, last 5 years——
Gross margin79.7%−54.0%
Operating margin−2,781.7%−21,982.6%
Net margin−2,725.8%−20,794.6%
Free cash flow—−$54M
Free cash flow margin—−15,553.4%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count77.9%15.4%
Last close$1.39$44.41
P/E at the last close——
Insider trades, last 12 months—bought $13.5 million, sold $2.9 million
Piotroski F-score—3 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Nexalin TechnologyPulse Biosciences
Operating margin
Percent of revenue
Nexalin TechnologyPulse Biosciences
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Nexalin TechnologyPulse Biosciences

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Nexalin Technology and Pulse Biosciences pages.